老年混合型肝癌患者肝脏增强CT和MRI影像学特征及诊断价值

doi:10.20047/j.issn1673-7210.2023.19.38

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (650 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨老年混合型肝癌（cHCC-CC）患者肝脏增强CT及MRI影像学特征及诊断价值。方法 2018年10月至2020年9月江苏省如皋市人民医院收治的98例拟诊为cHCC-CC的老年患者为研究对象，患者均行CT和MRI检查。分析老年cHCC-CC患者CT及MRI影像特征。以病理结果为金标准，分析CT、MRI影像学检查及两者联合检查对老年cHCC-CC患者的诊断价值。结果 98例拟诊为cHCC-CC的老年患者中cHCC-CC患者89例。CT平扫示肝脏轮廓欠规整，呈波浪状，体积增大，密度不均匀，肿瘤呈混合密度或低密度；MRI平扫呈镶嵌征象。肝脏增强CT、MRI影像及两者联合诊断老年cHCC-CC的灵敏度分别为77.53%、92.13%、97.75%；特异度分别为66.67%、77.78%、88.89%；准确度分别为76.53%、90.81%、96.94%。结论肝脏增强CT、MRI联合检测对老年cHCC-CC的诊断效能较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	肖志锋1　　杨志勇1　　钱小建1　　孙蓉1　　姜艳丽1　　肖翼春2▲

关键词 ：老年, 混合型肝癌, CT, MRI

Abstract：Objective To explore the imaging features and diagnostic value of liver enhanced CT and MRI in elderly patients with combined hepatocellular and cholangio carcinoma (cHCC-CC). Methods From October 2018 to September 2020, 98 elderly patients suspected to be cHCC-CC admitted to Rugao People’s Hospital, Jiangsu Province were selected as the research subjects, all patients underwent CT and MRI examinations. CT and MRI imaging features of elderly patients with cHCC-CC were analyzed. Pathological results as the gold standard, the diagnostic value of CT, MRI, and their combination in elderly patients with cHCC-CC was analyzed. Results Among the 98 elderly patients suspected to be cHCC-CC, 89 cases were cHCC-CC patients. CT plain scan showed that the liver contour was unstructured, wavy, with increased volume and uneven density, and the tumor presented mixed density or low density; plain MRI showed mosaic signs. The sensitivity of liver enhanced CT, MRI, and their combination in the diagnosis of elderly cHCC-CC was 77.53%, 92.13%, and 97.75%, respectively; the specificity was 66.67%, 77.78%, and 88.89%, respectively; the accuracy was 76.53%, 90.81%, and 96.94%, respectively. Conclusion The combination of enhanced CT and MRI in the diagnosis of cHCC-CC in the elderly is effective.

Key words： Elderly Combined hepatocellular and cholangio carcinoma CT MRI

基金资助:江苏省自然科学基金资助项目（BK20191153）。

通讯作者: ▲通讯作者

引用本文:

肖志锋1　　杨志勇1　　钱小建1　　孙蓉1　　姜艳丽1　　肖翼春2▲. 老年混合型肝癌患者肝脏增强CT和MRI影像学特征及诊断价值[J]. 中国医药导报, 2023, 20(19): 170-173.
XIAO Zhifeng1 YANG Zhiyong1 QIAN Xiaojian1 SUN Rong1 JIANG Yanli1 XIAO Yichun2▲. Imaging features and diagnostic value of enhanced CT and MRI in elderly patients with combined hepatocellular and cholangio carcinoma. 中国医药导报, 2023, 20(19): 170-173.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.19.38 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I19/170

[1] Sciarra A，Park YN，Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma [J]. Hum Pat- hol，2020，96（12）：48-55.
[2] Peng JB，Peng YT，Lin P，et al. Differentiating infected focal liver lesions from malignant mimickers：value of ultrasound-based radiomics [J]. Clin Radiol，2022，77（2）：104- 113.
[3] Schizas D，Mastoraki A，Routsi E，et al. Combined hepatocellular-cholangiocarcinoma：an update on epidemiology，classification，diagnosis and management [J]. Hepatobiliary Pancreat Dis Int，2020，19（6）：515-523.
[4] Ramai D，Ofosu A，Lai JK，et al. Combined hepatocellular cholangiocarcinoma：a population-based retrospective Stu- dy [J]. Am J Gastroenterol，2019，114（9）：1496-1501.
[5] 张瑜，刘秀峰，秦叔逵，等.混合型肝癌的临床特征和预后分析[J].临床肿瘤学杂志，2019，212（8）：71-75.
[6] 侯键.医学影像学[M].北京：中国中医药出版社，2013：43-45.
[7] 石木兰.肿瘤影像学（精）[M].北京：科学出版社，2006：28-31.
[8] 孙青，张成琪.肿瘤影像学与病理学诊断[M].北京：人民军医出版社，2013：334.
[9] Joseph NM，Tsokos CG，Umetsu SE，et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma [J]. J Pathol，2019，248（2）：164-178.
[10] Liu X，Khalvati F，Namdar K，et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning [J]. Eur Radiol，2021，31（1）：244-255.
[11] Ishii T，Ito T，Sumiyoshi S，et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma [J]. World J Surg Oncol，2020，18（1）：319-324.
[12] Krishna M. Pathology of cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma [J]. Clin Liver Dis，2021， 17（4）：255-260.
[13] Su YL，Ng CT，Jan YH，et al. Remarkable response to olaparib in a patient with combined hepatocellular-cholangiocarcinoma harboring a biallelic brca2 mutation [J]. Onco Targets Ther，2021，14（28）：3895-3901.
[14] Kim TH，Kim H，Joo I，et al. Combined hepatocellular- cholangiocarcinoma：changes in the 2019 world health organization histological classification system and potential impact on imaging-based diagnosis [J]. Korean J Radiol，2020，21（10）：1115-1125.
[15] Malone CD，Gibby W，Tsai R，et al. Outcomes of yttrium-90 radioembolization for unresectable combined biphenotypic hepatocellular-cholangiocarcinoma [J]. J Vasc Interv Radiol，2020，31（5）：701-709.
[16] Wang X，Wang W，Ma X，et al. Combined hepatocellular- cholangiocarcinoma：which preoperative clinical data and conventional mri characteristics have value for the prediction of microvascular invasion and clinical significance [J]. Eur Radiol，2020，30（10）：5337-5347.
[17] Anysz-Grodzicka A，Podgorska J，Cieszanowski A. State-of- the-art Mr Imaging of Uncommon Hepatocellular Tumours：Fibrolamellar Hepatocellular Carcinoma and Combined Hep- atocellularcholangiocarcinoma [J]. Curr Med Imaging Rev，2019，15（3）：269-280.
[18] Wang Y，Yang Q，Li S，et al. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a chinese population [J]. Clin Radiol，2019，74（5）：401-407.
[19] Granata V，Fusco R，Venanzio SS，et al. Diagnostic performance of LI-RADS in adult patients with rare hepatic tumors [J]. Eur Rev Med Pharmacol Sci，2022，26（2）：399-414.
[20] 刘英娜.混合型肝癌的CT及MRI影像学表现分析[J].中国CT和MRI杂志，2020，18（2）：88-91.
[21] Guo W，Pang Y，Yao L，et al. Imaging fibroblast activation protein in liver cancer：a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT [J]. Eur J Nucl Med Mol Imaging，2021，48（5）：1604-1617.
[22] Tsili AC，Alexiou G，Naka C，et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US，multidetector CT，MRI，and FDG PET/CT：a meta-analysis [J]. Acta Radiol，2021，62（3）：302-312.
[23] Shao L，Wang X，Yu Y，et al. Comparative analysis of the efficacy and accuracy of magnetic resonance imaging（MRI）and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization（TACE）in patients with primary liver cancer [J]. Transl Cancer Res，2021，10（8）：3739-3747.
[24] Rahimi A，Khalil A，Faisal A，et al. CT-MRI Dual Information Registration for the Diagnosis of Liver Cancer：A Pilot Study Using Point-based Registration [J]. Curr Med Imag- ing，2022，18（1）：61-66.
[25] Anderson MA，Dhami RS，Fadzen CM，et al. CT and MRI features differentiating mucinous cystic neoplasms of the liver from pathologically simple cysts [J]. Clin Imaging，2021， 76（9）：46-52.
[26] M Cunha G，Fowler KJ，Roudenko A，et al. How to Use LI- RADS to Report Liver CT and MRI Observations [J]. Radiographics，2021，41（5）：1352-1367.